2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

Ganglion cells

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

1

Fluorescent Dyes

4

Biochemical Assay Reagents

8

Peptides

1

Inhibitory Antibodies

2

Natural
Products

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15498
    Rimegepant
    5+ Cited Publications

    BMS-927711; BHV-3000

    		 CGRP Receptor Neurological Disease
    Rimegepant (BMS-927711) is an orally bioavailable and blood-brain barrier permeable antagonist of CGRP and AMY1 receptors, with a pIC50 of 8.01 and a Ki of 0.027 nM for human CGRP receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at CGRP and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to migraine .
    Rimegepant
  • HY-100714
    DL-AP5
    3 Publications Verification

    2-APV; DL-2-Amino-5-phosphonovaleric acid

    		 iGluR Neurological Disease Inflammation/Immunology
    DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina .
    DL-AP5
  • HY-100001
    SKF-96365 (hydrochloride)
    Maximum Cited Publications
    27 Publications Verification

    		 TRP Channel CRAC Channel Autophagy CaMK Akt Apoptosis Na+/Ca2+ Exchanger Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    SKF-96365 hydrochloride is a TRPC channel antagonist and store-operated calcium entry (SOCE) inhibitor. SKF-96365 hydrochloride reduces calcium ion influx by inhibiting the activity and expression of TRPC6, STIM1 and Orai1. SKF-96365 hydrochloride inhibits voltage-gated sodium current (cardiac INa/NaV1.5) and slows myocardial conduction. SKF-96365 hydrochloride inhibits phosphorylation/activation of CaMKIIγ and suppresses the downstream AKT signaling pathway. SKF-96365 hydrochloride induces G2/M phase cell cycle arrest, apoptosis and cytoprotective autophagy in colorectal cancer cells. SKF-96365 hydrochloride alleviates allergic rhinitis symptoms by reducing inflammatory cytokine levels. SKF-96365 hydrochloride reduces intracellular calcium overload, inhibits Homer1 expression, prevents nuclear damage and suppresses apoptosis. SKF-96365 hydrochloride inhibits the growth of colorectal cancer xenografts in nude mice . SKF-96365 hydrochloride is applicable to research related to allergic rhinitis, colorectal cancer, Parkinson's disease, persistent spontaneous nociception and hyperalgesia .
    SKF-96365 (hydrochloride)
  • HY-109061
    Lazertinib
    3 Publications Verification

    YH25448; GNS-1480

    		 Apoptosis Akt TRP Channel EGFR ERK Infection Neurological Disease Metabolic Disease Cancer
    Lazertinib (YH25448; GNS-1480) is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
    Lazertinib
  • HY-N6789
    KT5720
    4 Publications Verification

    		 PKA Neurological Disease Cancer
    KT5720 is a potent, cell-permeable, specific, reversible and ATP-competitive PKA inhibitor (IC50=3.3 μM). KT5720 is effective in reversing MDR1-mediated multidrug resistance. KT5720 also reduces the excitability of dorsal root ganglion (DRG) neurons by attenuating Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel activity and reducing intracellular Ca2 + concentrations. KT5720 can be used in the study of haematological malignancies as well as HCN and DRG neuron-related diseases .
    KT5720
  • HY-107661
    Arundic Acid
    2 Publications Verification

    ONO-2506; (R)-2-Propyloctanoic acid

    		 ERK Akt NF-κB EAAT Cardiovascular Disease Neurological Disease
    Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent. Arundic Acid increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt and NF-κB pathways. Arundic Acid attenuates retinal ganglion cell death in a normal-tension glaucoma model. Arundic Acid exerts neuroprotective effects in a mouse model of Parkinson's disease. Arundic Acid is a S100β protein synthesis inhibitor that prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats. Arundic Acid downregulates neuroinflammation and astrocytic dysfunction after status epilepticus in immature rats. Arundic Acid is applicable to research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage and epilepsy .
    Arundic Acid
  • HY-112624I
    Dextran T3 (MW 3,000)

    Dextran 3; Dextran D3; Dextran T3(MW 2400-3600)

    		 Bacterial Others
    Dextran T3 (Dextran 3; Dextran T3(MW 2400-3600)) is a neural tracer and intestinal permeability probe that can move anterogradely and retrogradely in neuronal axons by passive diffusion. Dextran T3 (MW 3,000) is able to permeate across the intestinal epithelial cell membrane in the presence of cholera toxin-induced cytoskeletal disturbance. Dextran T3 (MW 3,000) is used as a fluorescent marker to rapidly label developing neurons (such as Xenopus retinal ganglion cells) and to assess intestinal barrier function. It can be used to study axonal transport in neuroanatomy and permeability changes in intestinal pathophysiology. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
    Dextran T3 (MW 3,000)
  • HY-14608R
    L-Glutamic acid (Standard)

    		Reference Standards Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC50 & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
    L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
    In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
    L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
    L-Glutamic acid (Standard)
  • HY-109061B
    Lazertinib mesylate
    3 Publications Verification

    YH25448 mesylate; GNS-1480 mesylate

    		 TRP Channel EGFR Akt ERK Apoptosis Cancer
    Lazertinib (YH25448; GNS-1480) mesylate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
    Lazertinib mesylate
  • HY-120751
    TROX-1

    		Calcium Channel Neurological Disease
    TROX-1 is a selective, orally active and brain-penetrant N-type calcium channel (Cav2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .
    TROX-1
  • HY-B0600
    Tafluprost

    AFP-168; MK2452

    		 Prostaglandin Receptor Cardiovascular Disease Others
    Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn 2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma .
    Tafluprost
  • HY-P991413
    ZEB85

    		Trk Receptor ERK Akt p38 MAPK Neurological Disease Inflammation/Immunology
    ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .
    ZEB85
  • HY-N4102
    5,7-Dihydroxy-4-methylcoumarin

    		Apoptosis JNK FOXO Reactive Oxygen Species (ROS) Caspase Neurological Disease
    5,7-Dihydroxy-4-methylcoumarin is an antioxidant. 5,7-Dihydroxy-4-methylcoumarin protects mouse cochlear hair cells from Cisplatin-induced damage, enhances cell viability and inhibits apoptosis. 5,7-Dihydroxy-4-methylcoumarin downregulates phosphorylated JNK levels, increases the ratio of phosphorylated FoxO1 to total FoxO1, scavenges free radicals, reduces ROS accumulation, maintains mitochondrial membrane potential and alleviates mitochondrial dysfunction. 5,7-Dihydroxy-4-methylcoumarin downregulates the expression of caspase-3 and improves cell viability. 5,7-Dihydroxy-4-methylcoumarin can be used in studies related to ototoxicity .
    5,7-Dihydroxy-4-methylcoumarin
  • HY-B0416
    Gallamine Triethiodide

    		mAChR Adrenergic Receptor Neurological Disease
    Gallamine Triethiodide is a blood-brain barrier-permeable skeletal muscle relaxant. Gallamine Triethiodide induces skeletal muscle paralysis by blocking acetylcholine. Gallamine Triethiodide directly stimulates intracardiac β receptors. Gallamine Triethiodide prolongs the duration of afterdischarge in the cat cerebral cortex. Gallamine Triethiodide can be used in studies related to convulsive disorders .
    Gallamine Triethiodide
  • HY-P10227
    Xelafaslatide

    ONL-1204

    		 Fatty Acid Synthase (FASN) Apoptosis Interleukin Related Toll-like Receptor (TLR) NOD-like Receptor (NLR) Caspase Neurological Disease
    Xelafaslatide (ONL-1204) is a Fas receptor antagonist. Xelafaslatide blocks the Fas receptor signaling pathway and inhibits downstream apoptosis and inflammatory pathways. Xelafaslatide suppresses neuroinflammation and microglial activation in glaucoma models, protects retinal ganglion cells and prevents axonal degeneration. Xelafaslatide is applicable to relevant research on glaucoma .
    Xelafaslatide
  • HY-126195
    Fluoflavine

    ML-090

    		 NADPH Oxidase Neurological Disease
    Fluoflavine (ML-090) is a selective NOX1 inhibitor and reactive oxygen species inhibitor. Fluoflavine reduces reactive oxygen species production, NOX1-mediated downstream signaling events, and oxygen-glucose deprivation-induced retinal ganglion cell death. Fluoflavine inhibits NADPH oxidase activity and pathological retinal neovascularization induced by oxygen-induced retinopathy in the retinas of ischemic mice. Fluoflavine can be used in studies related to retinal ischemia-reperfusion injury and proliferative retinopathy .
    Fluoflavine
  • HY-119684
    Maresin 2

    		NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury .
    Maresin 2
  • HY-139192
    Brophenexin
    3 Publications Verification

    NMDAR/TRPM4-IN-2

    		 iGluR TRP Channel ERK Neurological Disease
    Brophenexin (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. Brophenexin shows neuroprotective activity. Brophenexin prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. Brophenexin protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .
    Brophenexin
  • HY-W540972
    Primulin

    Primuline

    		 Fluorescent Dye HCV Dengue Virus Infection
    Primulin is a versatile fluorescent dye and bioactive compound widely used in analytical, biological, botanical and virological studies. Primulin acts as a versatile stain that labels plant cell walls and differentiates live and dead spermatozoa via distinct fluorescence patterns. Primulin exhibits strong albumin‑binding capacity. Primulin acts as a retrograde axonal tracer in neurobiological investigations. Primulin and its derivatives inhibit HCV NS3, block dengue virus NS3-mediated ATP hydrolysis, and disrupt HCV replicase assembly .
    Primulin
  • HY-139201H
    Poly-D-lysine hydrobromide (MW ≥300000)

    PDLHB (MW ≥300000)

    		 CaSR Others
    Poly-D-lysine hydrobromide (MW ≥300000) (PDLHB (MW ≥300000)) is a cationic polymer and cell adhesion promoter. Poly-D-lysine hydrobromide (MW ≥300000) serves as a substrate coating to support the adhesion and proliferation of rat dorsal root ganglion satellite glial cells in vitro. Poly-D-lysine hydrobromide (MW ≥300000) promotes the adhesion and immobilization of cells on plastic culture dishes. Poly-D-lysine hydrobromide is also known as a calcium-sensing receptor (CaSR) agonist peptide .
    Poly-D-lysine hydrobromide (MW ≥300000)
  • HY-101359
    TPMPA

    		GABA Receptor Neurological Disease
    TPMPA, a hybrid of isoguvacine and 3-APMPA, is the first selective antagonist for a GABAC receptor (KB = 2.1 μM), but not to interact with GABAA (KB = 320 μM) or GABAB receptors (EC50 = 500 μM). TPMPA has the potential for the research of suppressing orientation selectivity in ganglion cells .
    TPMPA
  • HY-P10019
    Pegsebrenatide

    NLY01

    		 GCGR Neurological Disease Inflammation/Immunology
    Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .
    Pegsebrenatide
  • HY-100714C
    DL-AP5 sodium
    3 Publications Verification

    2-APV sodium; DL-2-Amino-5-phosphonovaleric acid sodium

    		 iGluR Neurological Disease Inflammation/Immunology
    DL-AP5 (2-APV) sodium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 sodium shows significantly antinociceptive activity. DL-AP5 sodium specifically blocks on channels in the rabbit retina .
    DL-AP5 sodium
  • HY-P1604
    ATX-II
    1 Publications Verification

    		 Sodium Channel Cardiovascular Disease Inflammation/Immunology
    ATX-II is a selective sodium channel modulator toxin. ATX-II enhances late sodium current, prevents full sodium channel inactivation, and generates persistent current fractions. ATX-II has pro-arrhythmic effect. ATX-II slows intrinsic heart rate, prolongs QT interval and sinus node recovery time, and causes sinus pauses and arrests. ATX-II can be used for the research of atrial fibrillation, long QT syndrome, and long QT3 syndrome .
    ATX-II
  • HY-P1604A
    ATX-II TFA
    1 Publications Verification

    		 Sodium Channel Cardiovascular Disease Inflammation/Immunology
    ATX-II TFA is a selective sodium channel modulator toxin. ATX-II TFA enhances late sodium current, prevents full sodium channel inactivation, and generates persistent current fractions. ATX-II TFA has pro-arrhythmic effect. ATX-II TFA slows intrinsic heart rate, prolongs QT interval and sinus node recovery time, and causes sinus pauses and arrests. ATX-II TFA can be used for the research of atrial fibrillation, long QT syndrome, and long QT3 syndrome .
    ATX-II TFA
  • HY-110122
    AZ 12216052
    1 Publications Verification

    		 mGluR Neurological Disease
    AZ 12216052 is a mGluR8 positive allosteric modulator, and helps mGluR8 modulate signaling inputing to retinal ganglion cells. AZ 12216052 exhibits antianxiety effect .
    AZ 12216052
  • HY-138649
    PB2

    		Influenza Virus Neurological Disease
    PB2 is a tris(2-carboxyethyl)phosphine (TCEP) analogue increasing retinal ganglion (RGCs) cells survival after axotomy in vitro at nanomolar and picomolar concentrations. PB2 is substantially more permeable than TCEP. PB2, as a reducing agent, is highly neuroprotective for RGCs .
    PB2
  • HY-125972
    zr17-2

    		Keap1-Nrf2 Heme Oxygenase (HO) Cardiovascular Disease Neurological Disease
    zr17-2 is a cold inducible RNA-binding protein (CIRBP) agonist. zr17-2 has anti-inflammatory and anti-oxidant and can be used for the study of myocardial infarction. zr17-2 is a hypothermia mimetic molecule that reduces oxidative stress-induced retinal cell death .
    zr17-2
  • HY-139192A
    Brophenexin free base
    3 Publications Verification

    NMDAR/TRPM4-IN-2 free base

    		 iGluR TRP Channel ERK Neurological Disease
    Brophenexin free base (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. Brophenexin free base shows neuroprotective activity. Brophenexin free base prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. Brophenexin free base protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .
    Brophenexin free base
  • HY-121964
    cis-Piperidine-2,3-dicarboxylic acid

    		iGluR Neurological Disease
    Cis-piperidine-2,3-dicarboxylic acid is a non-specific antagonist of NMDA, AMPA and kainate ionotropic receptors and a partial agonist for NMDA receptors. Cis-piperidine-2,3-dicarboxylic acid can be used in blocking general excitatory synaptic transmissions .
    cis-Piperidine-2,3-dicarboxylic acid
  • HY-W014700
    Glycyl-L-glutamic acid

    H-Gly-Glu-OH; Gly-Glu

    		 Cholinesterase (ChE) Neurological Disease
    Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration .
    Glycyl-L-glutamic acid
  • HY-125942
    SKF-96365
    Maximum Cited Publications
    27 Publications Verification

    		 CRAC Channel TRP Channel CaMK Akt Apoptosis Autophagy Na+/Ca2+ Exchanger Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    SKF-96365 is a TRPC channel antagonist and store-operated calcium entry (SOCE) inhibitor. SKF-96365 reduces calcium ion influx by inhibiting the activity and expression of TRPC6, STIM1 and Orai1. SKF-96365 inhibits voltage-gated sodium current (cardiac INa/NaV1.5) and slows myocardial conduction. SKF-96365 inhibits phosphorylation/activation of CaMKIIγ and suppresses the downstream AKT signaling pathway. SKF-96365 induces G2/M phase cell cycle arrest, apoptosis and cytoprotective autophagy in colorectal cancer cells. SKF-96365 alleviates allergic rhinitis symptoms by reducing inflammatory cytokine levels. SKF-96365 reduces intracellular calcium overload, inhibits Homer1 expression, prevents nuclear damage and suppresses apoptosis. SKF-96365 inhibits the growth of colorectal cancer xenografts in nude mice . SKF-96365 is applicable to research related to allergic rhinitis, colorectal cancer, Parkinson's disease, persistent spontaneous nociception and hyperalgesia .
    SKF-96365
  • HY-P5142
    ω-Hexatoxin-Hv1a

    ω-ACTX-Hv1; ω-Atracotoxin-HV1

    		 Insecticide Calcium Channel Apoptosis Necroptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca 2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .
    ω-Hexatoxin-Hv1a
  • HY-168758
    Delta3,5-cholestadien-7-one

    		GABA Receptor Neurological Disease
    Delta3,5-cholestadien-7-one is an oxysterol and a negative allosteric modulator of GABAA receptors. Delta3,5-cholestadien-7-one reduces GABA-induced currents in HEK cells expressing α1β1γ2 or α4β3γ2 subunit-containing GABAA receptors with IC50 values of 1.5 and 1 µM, respectively. Delta3,5-cholestadien-7-one reduces GABA-induced depolarization of peptidergic and non-peptidergic nociceptors, C-LTMRs, and cold thermosensors in isolated mouse dorsal root ganglion (DRG) neurons .
    Delta3,5-cholestadien-7-one
  • HY-158820
    Cosdosiran
    1 Publications Verification

    QPI-1007

    		 Small Interfering RNA (siRNA) Caspase Cardiovascular Disease
    Cosdosiran is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.
    Cosdosiran
  • HY-138648
    PB1

    		ERK Neurological Disease
    PB1 is a potent intracellular disulfide reducing agent with several advantages including good cell permeability, the ability to form a high intracellular concentration gradient, and stability. PB1 is a borane-protected TCEP (tris(2-carboxyethyl)phosphine) analogue. PB1 increases retinal ganglion cells survival after axotomy in vitro at nanomolar and picomolar concentrations. PB1 can be used for the research of neuroprotective .
    PB1
  • HY-10068
    Y-33075 hydrochloride

    Y-39983

    		 ROCK Neurological Disease
    Y-33075 hydrochloride (Y-39983) is a selective ROCK inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM.
    Y-33075 hydrochloride
  • HY-P10077
    GL189

    		Beta-secretase Neurological Disease
    GL189 is a β-secretase inhibitor. GL189 has neuroprotective effect, and can be used for research of neurodegenerative diseases .
    GL189
  • HY-19858
    LY-466195

    		iGluR Neurological Disease
    LY-466195 is a selective and competitive GLUK5 receptor antagonist. LY-466195 antagonizes Kainate-induced currents with an IC50 value of 0.045 μM in rat dorsal root ganglion neurons. In HEK293 cells transfected with GLUK5, GLUK2/GLUK5, or GLUK5/GLUK66 receptors, LY466195 produces IC50 values of 0.08 μM, 0.34 μM, and 0.07 μM, respectively .
    LY-466195
  • HY-175340
    Kv7.2/Kv7.3 activator-3

    		Potassium Channel TSPO Neurological Disease
    Kv7.2/Kv7.3 activator-3 (GRT-X) is an orally active Kv7.2/Kv7.3 and TSPO activator. Kv7.2/Kv7.3 activator-3 activates Kv7.2/Kv7.3, Kv7.4, and Kv7.5 with EC50 values of 0.37, 2.06, and 0.75 μM, respectively, and binds to TSPO with Ki values of 0.07 μM (rat membrane) and 4.60 μM (human U-118 MG cells). Kv7.2/Kv7.3 activator-3 prevents motor neuron degeneration in mice and humans conditioned by ALS/FTD astrocytes. Kv7.2/Kv7.3 activator-3 stimulates dorsal root ganglion axonal growth through TSPO and Kv7.2/3 activation. Kv7.2/Kv7.3 activator-3 has anti-epileptic effects in epileptic seizure models. Kv7.2/Kv7.3 activator-3 reduces pain hypersensitivity in patients with diabetic neuropathy, promotes neuronal survival and regeneration after cervical neuropathy in rats, and accelerates the recovery of normal function of sensory and motor neurons .
    Kv7.2/Kv7.3 activator-3
  • HY-B1661
    Hexamethonium chloride

    Hexone chloride

    		 Biochemical Assay Reagents Cardiovascular Disease Others
    Hexamethonium Chloride Dihydrate is a synthetic organic compound commonly used as a ganglion blocking agent, which means it blocks the transmission of nerve impulses between ganglion cells in the autonomic nervous system. Hexamethonium Chloride Dihydrate is used in various medical applications such as lowering blood pressure or inhibiting certain types of neuropathic pain. It works by inhibiting the release of acetylcholine, a neurotransmitter that plays a key role in regulating many bodily functions.
    Hexamethonium chloride
  • HY-130358
    PDDHV

    		Calcium Channel Neurological Disease
    PDDHV is a calcium absorption inducer and may achieve 45Ca 2+ influx by stimulating vanillic acid receptor VR1. PDDHV induces 45Ca 2+ uptake (EC50: 70 nM) in rat dorsal root ganglion neurons (expressing native vanilloid receptors) and calcium mobilization (EC50: 125 nM) in VR1-transfected CHO cells. PDDHV also inhibits [3H]-resiniferatoxin (RTX) binding to the dorsal root ganglion membrane in rats .
    PDDHV
  • HY-158820A
    Cosdosiran sodium
    1 Publications Verification

    QPI-1007 sodium

    		 Small Interfering RNA (siRNA) Caspase Cardiovascular Disease
    Cosdosiran sodium is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.
    Cosdosiran sodium
  • HY-P1384
    L803

    		Somatostatin Receptor Neurological Disease
    L803 is a selective Somatostatin Receptor Subtype 4 (SST4) agonist. L803 inhibits L-type calcium channel currents (ICa). L803 is promising for research of retinal ganglion cell (RGC) degenerative diseases (e.g., glaucoma) .
    L803
  • HY-B0600R
    Tafluprost (Standard)

    AFP-168 (Standard); MK2452 (Standard)

    		 Prostaglandin Receptor Reference Standards Cardiovascular Disease Others
    Tafluprost (Standard) is the analytical standard of Tafluprost. This product is intended for research and analytical applications. Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma [4] .
    Tafluprost (Standard)
  • HY-100714D
    DL-AP5 lithium

    2-APV lithium; DL-2-Amino-5-phosphonovaleric acid lithium

    		 iGluR Neurological Disease Inflammation/Immunology
    DL-AP5 (2-APV) lithium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 lithium shows significantly antinociceptive activity. DL-AP5 lithium specifically blocks on channels in the rabbit retina .
    DL-AP5 lithium
  • HY-100714R
    DL-AP5 (Standard)

    2-APV (Standard); DL-2-Amino-5-phosphonovaleric acid (Standard)

    		 Reference Standards iGluR Neurological Disease Inflammation/Immunology
    DL-AP5 (Standard) is the analytical standard of DL-AP5. This product is intended for research and analytical applications. DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina .
    DL-AP5 (Standard)
  • HY-100714CR
    DL-AP5 sodium (Standard)

    2-APV sodium (Standard); DL-2-Amino-5-phosphonovaleric acid sodium (Standard)

    		 Reference Standards iGluR Neurological Disease Inflammation/Immunology
    DL-AP5 (sodium) (Standard) is the analytical standard of DL-AP5 (sodium). This product is intended for research and analytical applications. DL-AP5 (2-APV) sodium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 sodium shows significantly antinociceptive activity. DL-AP5 sodium specifically blocks on channels in the rabbit retina .
    DL-AP5 sodium (Standard)
  • HY-151189
    ROCK-IN-4

    		ROCK Others
    ROCK-IN-4 is a potent ROCK inhibitor maintaining NO releasing ability. ROCK-IN-4 reversibly depolymerizes F-actin, and suppresses mitochondrial respiration in human trabecular meshwork (HTM) cells. ROCK-IN-4 can be used for glaucoma or ocular hypertension research .
    ROCK-IN-4
  • HY-180916
    CAII-IN-11

    		Carbonic Anhydrase Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Neurological Disease
    CAII-IN-11 (Compound A1) is a dual-target compound that contains a hCA II inhibitor (IC₅₀ = 2 nM) portion and a NO donor portion. CAII-IN-11 also has inhibitory activity against hCA IX, hCA XII, and hCA I, with IC50 values of 6, 3, and 152 nM respectively. CAII-IN-11 significantly increases the intracellular cGMP level in human trabecular meshwork cells. CAII-IN-11 reduces the apoptosis of retinal ganglion cells by reducing oxidative stress (ROS levels), inhibiting astrocytes and the NLRP3 inflammasome activation. CAII-IN-11 has hypotensive activity in rabbit models and can be used for the study of glaucoma .
    CAII-IN-11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: